TerminatedEUCTR 2004-000114-40
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with lithium or valproate in the treatmen...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesBipolarity
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Czechia and 1 more location
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 430
- Sponsor
- Novartis Pharma AG
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Austria, Czechia, Slovakia
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2004-000114-40
- Official title
Show the full official title
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with lithium or valproate in the treatmen...
Recruitment & locations
TerminatedAustria · Czechia · Slovakia
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharma AG, a pharmaceutical company.
Is this study still recruiting?
The historical registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of Bipolarity type I
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.